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ABSTRACT 
Objective: Synthesis of novel pyrazolines (P2-P4 & P7-P9) from the chalcones (C2-C10) obtained by condensing different aldehydes with 2-acetyl- 
5-bromothiophene and evaluates them for in vitro anticancer and anti-inflammatory activities. 
Methods: The synthesized pyrazolines and chalcones were screened for anticancer activity against human breast cancer cell lines-MCF-7 and MDA-
MB-468 in the range of 100 nm to 100 µm. Inhibition of bovine albumin denaturation and heat-induced hemolysis in vitro methods were followed to 
screen for anti-inflammatory activity. The structures of synthesized compounds were confirmed based on the IR, 1H NMR and mass spectral data. 
Results: Among the synthesized compounds, methoxy trisubstituted pyrazoline derivative (P6) exhibited an interesting profile of anticancer 
activity against MCF-7 cell line with GI50<0.1 μ M. similar to that of the standard drug doxorubicin. Compounds C8, P8, P3 have moderate anti-
inflammatory activity in bovine denaturation and heat induced hemolytic method. 
Conclusion: Novel pyrazolines and chalcones were synthesized and evaluated for anticancer and anti-inflammatory activity. The methoxy 
containing compounds one of which P6 found to be active against MCF-7 breast cancer cell line. The chloro-substituted compounds found to show 
anti-inflammatory activity. 
Keywords: Pyrazoline, Chalcone, MCF-7, MDA-MB-468, Anti-inflammatory, Anticancer. 
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INTRODUCTION 
For centuries, cancer has been prevailing as most serious disease and its 
incidence is rising day-to-day in the world. Cancer treatment usually falls 
into the category of surgery, radiation and chemotherapy. Despite of all 
these treatments, cancer is still continuing as uncontrollable disease and 
exploring for new approaches in anticancer therapy. Chemotherapy is 
generally used to treat cancer that has spread or metastasized because 
the medicines travel throughout the entire body. Recently, several 
substituted thiophenes and pyrazoles have been reported for anticancer 
activity. [1-4]. Pyrazoles substituted with another heterocyclic 
compound such as thiophene resulted in compounds with improved 
anti-proliferative activity against a number of solid and hematological 
tumors. [5] Even some prescribed drugs like omeprazole (proton pump 
inhibitor), eprosartan (angiotensin II receptor antagonist) and lore 
diplons (anxiolytic agent) have pyrazole ring connected with another 
heterocyclic moiety. Thiophene nucleus is also an important heterocyclic 
ring which is part of some of the drugs like raloxifene (osteoporosis), 
olanzapine (antipsychotic), and clopidogrel (antiplatelet agent). Thus, we 
were interested in synthesizing thiophene substituted pyrazolines and 
look for their anti-proliferative activity.  
As a part of our research work, we synthesized a series of 1-(5-
bromothiophen-2-yl)-3-(phenyl) prop-2-en-1-one and 1-(3-(5-
bromo-thiophene-2-yl)-5-(aryl)-4,5-dihydropyrazole-1-yl) ethanone 
and tested biologically. The method followed for the synthesis of the 
final compounds is in accordance with the literature [6]. Later, the 
anticancer activity of compounds was reported by screening against 
human breast cancer cell lines MCF-7 and MDA-MB-468 and in vitro 
anti-inflammatory activity was done by inhibition of bovine albumin 
denaturation method and heat induced hemolytic method. 
MATERIALS AND METHODS 
Chemistry 
Melting points of the compounds were determined using open 
capillary melting point apparatus and were reported uncorrected. 
Ultraviolet, visible spectroscopic analysis has been carried out in UV-
visible double beam spectrophotometer (LAB INDIA 3000+), IR 
spectra was recorded by a KBr pellet method using a bruker FTIR 
ALPHA transmission mode spectrophotometer. The 1H NMR spectra 
were recorded in DMSO-d6 by NMR 300MHZ spectrometers using 
tetramethyl silane as an internal standard. All the chemicals and 
solvents used in this study were of analytical grade (S. D. FINE Chem. 
Limited, Mumbai). Reaction progress was checked by TLC in a solvent-
vapor-saturated chamber on glass plates coated with Silica Gel GF254 
followed by visualization under UV light (254 nm). The solvent system 
used for thin layer chromatography was n-hexane: ethyl acetate (8:2). 
Preparation of chalcones 
0.01 Mol (2.05g) of 2-acetyl-5-bromothiophene taken in a 100 ml 
round bottom flask containing 20 ml of ethanol, to that equimolar 
quantity of substituted benzaldehydes added. The contents of the 
flask were stirred continuously using a magnetic stirrer, and the 
temperature was maintained below 20 ° C. Then 0.1 ml of 40% KOH 
was added drop by drop to the flask. The reaction was monitored by 
using a precoated TLC plate. After completion of the reaction, the 
contents of the flask were neutralized with dilute HCl to get 
precipitates of chalcones & filtered, washed with cold ethanol, dried 
and recrystallized from ethanol.  
Preparation of 2-pyrazolines 
0.002 moles of chalcone, 0.008 mole of hydrazine hydrate were 
taken in a 100 ml round bottom flask containing 30 ml of glacial 
acetic acid and refluxed for 70 h at 140 °C. The reaction mixture was 
monitored by using a precoated TLC plate. After completion of the 
reaction the content of the flask was poured into the crushed ice to get 
brown precipitate. The precipitate was dried and purified by column 
chromatography. Different gradients of ethyl acetate: petroleum ether, 
i.e. 2%, 4%, 6%, 8%, 10% and 12% was used to elute the pure 
compound successively. The eluent containing the compound was 
collected separately and evaporated to get the pure compound. 
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Table 1: List of synthesized compounds












































Reddy et al. 


































































Reddy et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 247-254 
250 
In vitro anticancer activity by SRB assay [18] 
The effect of synthesized compounds on cell growth was determined 
on two human tumor cells MCF-7 & MDA-MB-468. The 
sulforhodamine B (SRB) assay is used for cell density determination, 
based on the measurement of cellular protein content. The method 
described here has been optimized for the toxicity screening of 
compounds to adherent cells in a 96-well format. After an incubation 
period, cell monolayers are fixed with 10% (Wt/Vol) trichloroacetic 
acid and stained for 30 min with 0.4% (Wt/Vol) SRB dissolved in 1% 
acetic acid after which the excess dye was removed by repeatedly 
washing with 1% (Vol/Vol) acetic acid. The protein-bound dye was 
dissolved in 10 mM tris base solution for OD determination at 564 
nm using a microplate reader. 
 Appropriate positive controls were run in each experiment, and 
each experiment was repeated thrice. 
 Results are in terms of 
GI50 (concentration of the compound that produces 50% inhibition 
of the cells), 
TGI (concentration of the compound that produces total inhibition 
of the cells) and 
LC50 (concentration of the compound that kills 50% of the cells)  
 Compounds with GI50 ≤ 1µM was considered as active ones. 
 Doxorubicin was taken as a positive control.  
In vitro anti-inflammatory activity [19-21] 
Inhibition of bovine albumin denaturation method  
To 2 ml of various concentrations of test or standard solutions, 2.8 
ml of normal saline (pH=7.4) and 0.2 ml of 1% bovine albumin 
solution was added. Simultaneously blank samples were prepared 
for each concentration without the addition of 1% bovine albumin 
solution and an equal volume of normal saline (pH 7.4) was added to 
each blank sample. To 4.8 ml of normal saline (pH 7.4), 0.2 ml of 1% 
bovine albumin solution was added and used as a control. The 
test/standard samples were incubated for 15 min at 70 ° C. Then the 
tubes were cooled under running tap water and then absorbance 
was recorded at 660 nm. % inhibition of denaturation of bovine 
albumin was calculated using the formula, 
% Inhibition = ⟦(A − A1) ÷ A⟧ × 100 
Where A=absorbance of the control,  
A1= absorbance of the test/standard 
Heat-induced hemolytic method  
To 1 ml of various concentrations of test or standard solutions, 1 ml 
of 1% RBC’s suspension was added. Simultaneously blank samples 
were prepared for each concentration without the addition of 1% 
RBC’s solution and an equal amount of normal saline was added to 
each blank sample. An equal amount of 1% RBC’s solution and 
normal saline was added and was used as a control. 
All these samples were taken into centrifuge tubes and incubated in 
a water bath at 56 °C for 30 min. The tubes were cooled under 
running tap water and then centrifuged at 2500 rpm for 15 min and 
absorbance of the supernatant was taken at 560 nm. % inhibition 
was calculated using formula: 
% Inhibition = ⟦(A − A1) ÷ A⟧ × 100 
Where A=absorbance of the control, A1= absorbance of the 
test/standard. 
IC50 values 
IC50 was calculated using GraphPad prism software  
Statistical analysis 
All the data were expressed as mean±SEM. Statistical significance 
was tested by using one-way ANOVA followed by the Turkey’s test 
using a computer-based fitness program (Graph pad prism 5) 
RESULTS AND DISCUSSION 
Synthesis 
Claisen-Schmidt condensation reaction between 2-acetyl-5-
bromothiophene and different substituted aldehydes catalysed by 
40% KOH gave chalcones (C2-C10). The obtained chalcones were 
cyclised in the presence of glacial acetic acid to give 2-pyrazoliones 
(P2-P4 & P7-P9) (Scheme-I). All the synthesized compounds were 
characterized by FT IR, 1NMR and mass spectroscopic data. 
In the IR spectra of 1-(5-bromothiophen-2-yl)-3-(phenyl)prop-2-en-
1-one (C2-C10) characteristic absorption due to a carbonyl group 
appears in the range of 1655-1630 cm-1. The olefinic double (C=C) 
appears in the range of1593-1522 cm-1. The 1HNMR spectra, the two 
olefinic protons (CH=CH) appears as a doublet in the region of δ 6.9-
7.9 ppm and trans type of geometrical isomerism can be confirmed 
due to J>14. The thiophene protons seen as doublets were 
distinguished from other aromatic protons based on the J value 
which is 4. Aromatic protons of the benzene appear as a complex 
multiple in the range of δ 6.8-8.3 ppm.  
The IR spectra of 1-(3-(5-bromothiophene-2-yl)-5-(aryl)-4, 5-
dihydropyrazole-1-yl) ethanone (P2-P4 &P6-P9), the characteristic 
absorption due to a carbonyl group appears in the range of 1673-
1645 cm-1. The absorption of C-Br stretching appears in the range of 
580-591 cm-1. 1H NMR data showed Ha, Hb, Hx type of coupling due 
to spin coupling of CH2 protons with CH proton of the pyrazoline 
nucleus with doublet of doublets around δ 3.099 ppm (1H, dd, Ha), δ 
3.811 ppm (1H, dd, Hb), and δ 5.646 ppm (1H, dd, Hx) respectively, 
with coupling constants(Jab=17.6, Jax=5.2, Jbx=11.6). The thiophene 
protons were in the range of δ 7.03 to 6.9 ppm as a doublet with J 
value of 4. The phenyl protons were lying in the region of δ 6.3 to 8.2 
ppm with J values 7-9 depending on the type of substitution on the 
phenyl ring. The acetyl protons on the pyrazoline nucleus were 
present as a single and had δ value of 2.3 to 2.4 ppm. Thus, all the 
protons of pyrazoline compounds were accounted. 
Spectral data of compounds 
Compound C 2:(2E)-1-(5-bromothiophen-2-yl)-3-(4-nitro-
phenyl)prop-2-en-1-one 
IR (KBr)Vmax in cm-1:C=O str =1649.16, C=C str =1586.86, Ar-H str 
=3076.73, =C-H str = 2924.13,Ar-N-O str =1516.82, C-Br str = 
670.70; 1H NMR (CDCl3) in δ (ppm): 7.197 (d, 1H, C4 of 
thiopheneJ=4), 7.638 (d, 1H, C3 of thiophene J=4), 7.39 & 7.868 (d, 
2H,-CH=CH-trans J=15.6), 7.79 & 8.29 (d, 4H,Ar-HJ=8.8& J=8.4). 
Compound C 3:(2E)-1-(5-bromothiophen-2-yl)-3-(4-chloro-
phenyl) prop-2-en-1-one 
IR (KBr)Vmax in cm-1: C=O str =1650.08, C=C str =1593.94, Ar-H str 
=3072.28 cm-1, Ar-C=C str =1491.88, =C-H str = 2924.94, C-Clstr = 
771.88; 1H NMR (CDCl3) in δ (ppm): 7.16 (d, 1H, C4 of thiopheneJ=4), 
7.30 (d, 1H, C3 of thiophene), 7.805 (d, 1H,-CH=CH-trans J=15.6), 7.6 
(m, 1H,-CH=CH-trans J=17.6), 7.42 (d, 2H, orthoAr-H J=8.4) & 7.56 
(d, 2H Meta Ar-H J=8.4) 
Compound C 4:(2E)-1-(5-bromothiophen-2-yl)-3-(4-methoxy-
phenyl)prop-2-en-1-one 
IR (KBr)Vmax in cm-1: Aliphatic C-H str = 2838.82, C=O str =1645.48, 
C=C str =1587.27, Ar-H str =3084.58, Ar-C=C str =1510.30, =C-H str = 
3004.19, C-O-C str = 1302.44, 1031.93;1H NMR (CDCl3) in δ (ppm): 
7.15 (d, 1H, C4 of thiophene J=4),7.575 (d, 1H, C3 of thiophene), 7.83 
(d, 1H,-CH=CH-trans J=15.6), 7.218 (d 1H,-CH=CH-trans J=15.6), 7.606 
(m, 2H,orthoAr-H J=8.8) & 6.952 (d, 2H, meta Ar-H J=8.4) 3.86(s, 
3H,para Ar-OCH3). 
Compound C 5:(2E, 4E)-1-(5-bromothiophen-2-yl)-5-phenyl-
penta-2, 4-dien-1-one 
IR (KBr)Vmax in cm-1: C=O str =1634.88, C=C str =1572.08, Ar-H str 
=3105.88, Ar-C=C str =1572.08, 1445.91, =C-H str = 3025.17, C-Br 
str = 686.29;1H NMR (CDCl3) in δ (ppm): 7.13 (d, 1H, C4 of 
thiopheneJ=4),7.52 (m, 1H C3 of thiophene), 6.906 (d, 1H,-CH=CH-
trans J=14.8), 7.65 (m, 1H,-CH=CH-trans J=15.48), 6.98 (m, 1H,-
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CH=CH-trans), 7.03 (m, 1H,-CH=CH-trans) 7.516 (m, 2H,orthoAr-H 
J=8.4) & 7.314 to 7.402 (m, 3H, meta & paraAr-H). 
Compound C 6:(2E)-1-(5-bromothiophen-2-yl)-3-(3, 4, 5-tri-
methoxyphenyl) prop-2-en-1-one 
IR (KBr) Vmax in cm-1: Aliphatic C-H str = 2938.37,C=O str =1645.24, 
C=C str =1522.50, Ar-H str =3113.22, Ar-C=C str =1499.61, =C-H str 
= 3004.74, C-O-C str = 1214.49, C-Br str = 681.35;1H NMR (CDCl3) in 
δ (ppm):7.2 (m,1H, C4 of thiopheneJ=4),7.618 (d, 1H, C3 of 
thiophene), 7.15 (m, 1H,-CH=CH-), 7.79 (d, 1H,-CH=CH-trans J=15.6), 




IR (KBr) Vmax in cm-1: Aliphatic C-H str = 2834.62, C=O str 
=1639.66, C=C str =1570.53, Ar-H str =3079.72, Ar-C=C str 
=1511.08, =C-H str = 2933.22, C-O-C str = 1254.11, C-Br str = 
591.60 cm-1; 1H NMR (CDCl3) in δ (ppm): 7.197 (s, 1H, C4 of 
thiopheneJ=4), 7.6 (d, 1H, C3 of thiophene), 7.245 (m, 1H,-CH=CH-
), 7.815 (d, 1H,-CH=CH-trans J=15.2), 6.89 (d, 1H, meta Ar-H), 3.95 
(s, 6H, meta, para (Ar-OCH3)2). 
Compound C 8:(2E)-1-(5-bromothiophen-2-yl)-3-(2-chloro-
phenyl) prop-2-en-1-one 
IR (KBr) Vmax in cm-1: C=O str =1655.14, C=C str =1593.94, Ar-H str 
=3092.02, Ar-C=C str =1471.55, =C-H str = 2622.64, C-Clstr = 
775.32, C-Br str = 689.31; 1H NMR (CDCl3) in δ (ppm):7.167 d (1H 
C4 of thiopheneJ=4),7.601 d (1H C3 of thiophene), 7.089 m (1H,-
CH=CH-), 8.236 (d, 1H,-CH=CH-trans J=15.6), 7.735 (dd, 1H 
orthoAr-H),7.466 (dd, 1H, meta Ar-H), 7.319 to 7. 372 (m, 2H, 
meta, paraAr-H). 
Compound C 9: (2E)-1-(5-bromothiophen-2-yl)-3-phenylprop-
2-en-1-one 
IR (KBr) Vmax in cm-1: C=O str =1649.12, C=C str =1593.26, Ar-H str 
=3074.07, Ar-C=C str =1521.14, =C-H str = 3027.33, C-Br str = 
685.59;1H NMR (CDCl3) in δ (ppm): 7.161 (d, 1H, C4 of 
thiopheneJ=4),7.60 (d, 1H, C3 of thiopheneJ=4), 7.06 (m, 1H,-CH=CH-), 
7.863 (d, 1H,-CH=CH-trans J=15.6), 7.646 (m, 2H,orthoAr-H), 7.419 
to 7. 434 (m, 3H, 2 meta, 1paraAr-H). 
Compound C 10: (2E)-1-(5-bromothiophen-2-yl)-3-[4-(propan-
2-yl) phenyl] prop-2-en-1-one 
IR (KBr) Vmax in cm-1: Aliphatic C-H str = 2868.78, C=O str =1640.69, 
C=C str =1588.90, Ar-H str =3078.10, =C-H str = 2957.41, CH3 
bending= 1412.45;1H NMR (CDCl3) in δ (ppm): 7.157 (d, 1H, C4 of 
thiopheneJ=4),7.585 (m, 1H, C3 of thiophene), 7.275(m, 1H,-CH=CH-), 
7.853 (d, 1H,-CH=CH-trans J=15.6), 7.559 (m, 2H, orthoAr-H), 7.297 
(m, 2H, meta Ar-H), 2.95 (septet, 1H, CH of isopropyl), 1.282 & 1.265 
(6H–(CH3)2). 
Compound P 2: 1-[3-(5-bromothiophen-2-yl)-5-(4-nitrophenyl)-
4, 5-dihydro-1H-pyrazol-1-yl]ethanone 
IR (KBr) Vmax in cm-1: Aliphatic C-H str = 2925.85, C=O str =1666.37, 
Ar-C=C str =1605.79 cm-1, 1514.99, Ar-H str =3107.29, Ar-N-O str 
=1514.99,1216.40, C-Br str = 587.26; 1H NMR (CDCl3) in δ (ppm): 
2.37(s, 3H,-CH3,), 3.099 (dd, 1H, Ha), 3.811 (dd, 1H, Hb), 5.646 (dd, 
1H, Hx), 8.21 (d, 2H,Ar-H, J=8.4 HZ), 7.40 (d, 2H, Ar-H, J=8.4), 7.036 
to 6.928 (dd, 2H, thiopheneH), (Jab=17.6, Jax=5.2, Jbx=11.6) 
 
Table 2: Physico-chemical characterization data of synthesized chalcones of scheme I 
Code Molecular formula Molecular weight Melting point (ºC) % yield (%) Rf value* Colour 
C2 C13H8BrNO3S 338.17 193-196 72 0.62 Yellow flakes 
C3 C13H8BrClOS 327.62 135-138 67 0.64 Creamish white Amorphous 
C4 C14H11BrO2S 323.20 128-130 82 0.70 Cream 
C5 C15H11BrOS 319.21 128-130 86 0.68 Light yellow Crystalline needles 
C6 C16H15BrO4S 383.25 140-143 82 0.59 Yellow; Crystalline needles 
C7 C15H13BrO3S 353.23 103-106 64 0.62 Dark Yellow; Crystalline needles 
C8 C13H8BrClOS 327.62 123-126 60 0.67 Cream; Amorphous 
C9 C13H9BrOS 293.17 70-73 63 0.58 Light yellow; Crystals 
C10 C16H15BrOS 335.25 78-80 60  0.62 Cream; Amorphous 
P2 C15H12BrN3O3S 394.24 143-145 71 0.56 Creamy crystals 
P3 C15H12BrClN2OS 383.69 188-189 68 0.58 White crystals 
P4 C16H15BrN2O2S 379.27 159-160 95 0.60 Creamy crystals 
P6 C18H19BrN2O4S 439.32 90-92 78  0.64 Yellow crystals 
P7 C17H17BrN2O3S 409.29 116-118 79 0.58 Creamy crystals 
P8 C15H12BrClN2OS 383.69 180-183 86 0.56 Light brown crystals 
P9 C15H13BrN2OS 349.24 200-202 76 0.58 Dark brown crystals 
*n-Hexane: Ethyl acetate (8:2)  
 
Compound P 3: 1-[3-(5-bromothiophen-2-yl)-5-(4-chloro-
phenyl)-4,5-dihydro-1H-pyrazol-1-yl]ethanone 
IR (KBr) Vmax in cm-1: Ali C-H str = 2929.09, C=O str =1645.67, Ar-C=C 
str =1524.49, Ar-H str =3060.76, C-Br str = 580.79, C-Clstr = 626.89; 1H 
NMR (CDCl3) in δ (ppm): 2.35(s, 3H,-CH3,), 3.07 (dd, 1H, Ha), 3.73 (dd, 
1H, Hb), 5.55 (dd, 1H,Hx), 7.30 (d, 2H, Ar-H, J=8.4 HZ), 7.16 (d, 2H, Ar-
H, J=8.4), 6.921 (s, 1H, C-2 H of thiophene), 7.024 (s, 1H, C-3 H of 
thiophene),(Jab=17.6, Jax=4.8, Jbx=11.6); ESI-MS 385 (M+H)+. 
Compound P 4: 1-[3-(5-bromothiophen-2-yl)-5-(4-methoxy-
phenyl)-4,5-dihydro-1H-pyrazol-1-yl]ethanone 
IR (KBr) Vmax in cm-1: Aliphatic C-H str = 2840.59, C=O str =1657.18, 
Ar-C=C str =1514.32, Ar-H str =3064.73, C-Br str = 582.28, Ar-C-O-C 
str = 1248.50, 1028.05 cm-1; 1H NMR (CDCl3) in δ (ppm): 2.34(s, 3H,-
CH3,), 3.1 (dd, 1H, Ha), 3.703 (dd, 1H, Hb), 3.77 (s, 3H, p-Ar-OCH3) 
5.55 (dd, 1H, Hx), 7.154 (d, 2H, Ar-H, J=8.4), 6.855 (d, 2H, Ar-H, 
J=8.4), 6.921 (s, 1H, C-2 H of thiophene), 7.019 (s, 1H, C-3 H of 
thiophene), (Jab=17.6, Jax=4.8, Jbx=11.6); ESI-MS 381 (M+H)+. 
Compound P 6: 1-[3-(5-bromothiophen-2-yl)-5-(3, 4, 5-
trimethoxyphenyl)-4, 5-dihydro-1H-pyrazol-1-yl]ethanone 
IR (KBr) Vmax in cm-1:Aliphatic C-H str = 2826.52, C=O str =1664.80, 
Ar-C=C str =1506.84, Ar-H str =3085.12, C-Br str = 591.83, Ar-C-O-C 
str = 1237.66, 1006.90; 1H NMR (CDCl3) in δ (ppm): 2.38(s, 3H,-
CH3,), 3.1 (dd, 1H, Ha), 3.7 (dd, 1H, Hb), 3.80 (s, 3H, p-Ar-OCH3), 
3.826 (s, 6H, m-Ar-(OCH3)2), 5.521 (dd, 1H, Hx), 7.154 (d, 2H, Ar-H, 
J=8.4 HZ), 6.399 (d, 2H, Ar-H, J=8.4), 6.927 (s, 1H, C-2 H of 
thiophene), 7.027 (s, 1H, C-3 H of thiophene), (Jab=17.6, Jax=4.8, 
Jbx=11.6); ESI-MS 441 (M+H)+. 
Compound P 7: 1-[3-(5-bromothiophen-2-yl)-5-(3,4-dimethoxy-
phenyl)-4,5-dihydro-1H-pyrazol-1-yl]ethanone 
IR (KBr) Vmax in cm-1: Aliphatic C-H str = 2834.71, C=O str =1657.64, 
Ar-C=C str =1518.62, Ar-H str =2999.84, C-Br str = 578.98, Ar-C-O-C 
str = 1258.43, 1025.12; 1H NMR (CDCl3) in δ (ppm): 2.36(s, 3H,-CH3,), 
3.11 (dd, 1H, Ha), 3.71 (dd, 1H, Hb), 3.83 (s, 3H, p-Ar-OCH3), 3.85 (s, 
3H, m-Ar-(OCH3), 5.54 (dd, 1H, Hx), 6.76 (d, 2H, Ar-H, J=9.6 HZ), 6.81 
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(d, 1H, Ar-H, J=8), 6.92 (s, 1H, C-2 H of thiophene), 7.025 (s, 1H, C-3 H 
of thiophene), (Jab=17.6, Jax=4.4, Jbx=11.6); ESI-MS 411 (M+H)+. 
Compound P 8: 1-[3-(5-bromothiophen-2-yl)-5-(3-chloro-
phenyl)-4,5-dihydro-1H-pyrazol-1-yl]ethanone 
IR (KBr) Vmax in cm-1: Aliphatic C-H str = 2927.73, C=O str =1673.45, 
Ar-C=C str =1530.85, Ar-H str =3325.17, C-Clstr = 635.24; 1H NMR 
(CDCl3) in δ (ppm): 2.42(s, 3H,-CH3,), 3.01 (dd, 1H, Ha), 3.83 (dd, 1H, 
Hb), 5.92 (dd, 1H, Hx), 7.22 (m, 2H, Ar-H, J=4.4 HZ), 7.05 (m,1H, p, 
Ar-H, J=9.2), 7.406 (m, 1H,meta, Ar-H, J=9.2), 7.003 to 6.909 (dd, 2H, 
thiopheneH), (Jab=17.6, Jax=4.8, Jbx=11.6); ESI-MS 385 (M+H)+. 
Compound P 9: 1-[3-(5-bromothiophen-2-yl)-5-phenyl-4,5-
dihydro-1H-pyrazol-1-yl]ethanone 
IR (KBr) Vmax in cm-1: C=O str =1659.68, Ar-C=C str =1452.02, Ar-H 
str =3085.56, C-Br str = 577.14; 1H NMR (CDCl3) in δ (ppm):2.36(s, 
3H,-CH3,), 3.11 (dd, 1H, Ha), 3.73 (dd, 1H, Hb), 5.59 (dd, 1H, Hx), 6.91 
(s, 1H, C-2 H of thiophene), 7.016 (s, 1H, C-3 H of thiophene), 
(Jab=17.6, Jax=4.8, Jbx=11.6), 7.2 (s,1H, p-Ar-H,), 7.21 (d, 2H, ortho-Ar-
H, J=7.2), 7.3 (2H, m, meta-Ar-H, J=7.2); ESI-MS 351 (M+H)+. 
Biological activities 
The synthesized compounds were evaluated for their anticancer 
activity in selected human breast cancer cell lines MCF-7 and MDA-
MB-468. IC50 values, defined as the concentration corresponding to 
50% growth inhibition were based on concentration and exponential 
cell growth curves as shown in fig. 1-4. The compounds that exhibit 
GI50 ≤ 1 µM are considered to be active. All the compounds exhibited 
significant anticancer activity with GI50 values ranging from<0.1 
to>100 µM, while the positive control doxorubicin demonstrated the 
GI50<0.1µM in the cell lines employed. Compound P6 exhibits an 
interesting profile of anticancer activity with MCF-7 cell line with 
GI50<0.1 µM. Even the activity of P6 in MDA-MB-468 cell line was also 
found to be GI50 = 36.6 µM, which is the best activity when compared 
to all other compounds.  
The promising results shown by compound P6 on both cell lines 
suggest that it has potent broad-spectrum anticancer activity. 
However, compounds P2-P4 and P7-P9 also expressed significant 
activity values of GI50<100 µM in MCF-7 breast cancer cell lines. 
Whereas, in anticancer activity assay against MDA-MB-468 cell lines 
compound P8 shown GI50 value 57.2 µM and rest all shown GI50>100 
µM. C6 and P6 having tri-methoxy substitution showed GI50 (µ molar 
concentration of drug/compound causing 50% inhibition of the cell 
growth) value of 28.6 µM and<0.1 µM respectively against MCF-7 
breast cancer cell lines. C7 having dimethoxy substitution and P6 
having tri-methoxy substitution has GI50 value of 16.7 µM and 36.6 µM 
respectively against MDA-MB-468 breast cancer cell lines. Doxorubicin 
was the standard drug which has GI50 value of<0.1 µM. The other 
compounds have GI50 value greater than 16 µM. Concentrations of the 
test material used were 10, 20, 40 and 80µg/ml. 
The in vitro anti-inflammatory activity was performed by 
inhibition of bovine albumin denaturation method and heat 
induced hemolytic method. The inhibitory activity of the 
compounds was compared with the control and the significance 
factor “p” was less than 0.001 for all the compounds. The 
compound with chloro group as a substituent showed the highest 
inhibition activity suggesting that electron donating groups may 
aid the activity (table 3-6). The inhibitory activity of the 
compounds was compared with the control and the significance 
factor “p” was less than 0.001 for all the compounds. 
 
 
Fig. 1: % Control growth in human breast cancer cell line MCF-7 
 
 
Fig. 2:% Control growth in human breast cancer cell line MDA-
MB-468
 
Table 3: Bovine albumin denaturation method 
Conc. (μg/ml) % Inhibition±SEM* 























































































































IC50 (μg/ml) 7.873 76.40 68.0 62.80 156.62 46.28 241.6 46.249 98.0 78.92 
*All the values are average of three readings, mean±SEM, SEM = Standard Error Mean IC50= Half maximal inhibitory concentration. 
 
Reddy et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 247-254 
253 
Table 4: Bovine albumin denaturation method 
Conc. (μg/ml) % Inhibition±SEM* 



































































































7.873 63.89 48.69 59.90 189.50 65.24 39.42 43.89 
*All the values are the average of three readings, mean±SEM, SEM = Standard Error Mean, IC50= Half maximal inhibitory concentration 
 
Table 5: Heat-induced hemolytic method 
Conc. (μg/ml) % Inhibition±SEM* 

























































































































IC50 (μg/ml) 8.624 62.46 67.24 68.63 166.20 66.68 221.8 42.86 110.0 76.46 
*All the values are the average of three readings, mean±SEM, SEM = Standard Error Mean IC50= Half maximal inhibitory concentration 
 
Table 6: Heat-induced hemolytic method 
Conc. (μg/ml) % Inhibition±SEM* 

































































































IC50 (μg/ml) 8.624 64.90 56.60 68. 0 141.0 59.20 176.04 68.38 
*All the values are average of three readings, mean±SEM, SEM = Standard Error Mean IC50= Half maximal inhibitory concentration 
 
CONCLUSION 
The synthesis of chalcones and condensing them to form pyrazolines 
was done according to the reported methods. The synthesized 
chalcones and pyrazolines were screened for anti-tumor activity 
against human breast cancer cell lines-MCF-7 and MDA-MB-468. 
Compound P6 was found to be an active agent against human breast 
cancer cell lines-MCF7. The same compound showed anticancer 
activity against human breast cancer cell lines MDA-MB-468 but not 
as active as against cancer cell lines-MCF. The anti-inflammatory 
activity also established in all the synthesized compounds shown 
significant inhibition.  
The compounds C8, P3 and P8 shown moderate anti-inflammatory 
activity. It is found that the compounds with chloro substitution 
have in vitro anti-inflammatory activity. 
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